Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1D | P28221 | 20/20 | 0.78 |
| ▸ | HTR1B | P28222 | 11/20 | 0.78 |
| ▸ | DRD2 | P14416 | 3/20 | 0.56 |
| ▸ | HTR2A | P28223 | 3/20 | 0.56 |
| ▸ | HTR1A | P08908 | 3/20 | 0.56 |
| ▸ | DRD4 | P21917 | 1/20 | 0.56 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27563581 | 1.00 | HTR1D (0.78) | HTR1DHTR1BDRD2HTR2AHTR1A | |
| SCHEMBL6812051 | 0.88 | HTR1D (1.00) | HTR1DHTR1BDRD2HTR2AHTR1A | |
| SCHEMBL5090634 | 0.84 | HTR1D (0.63) | HTR1DHTR1BDRD2HTR2AHTR1A | |
| SCHEMBL8550171 | 0.84 | HTR1D (0.76) | HTR1DHTR1BDRD2HTR2AHTR1A | |
| SCHEMBL6811594 | 0.82 | HTR1D (0.82) | HTR1DHTR1BDRD2HTR1ASLC6A4 | |
| SCHEMBL6812692 | 0.82 | HTR1D (0.82) | HTR1DHTR1BDRD2HTR1ASLC6A4 | |
| SCHEMBL6812810 | 0.81 | HTR1D (0.75) | HTR1DHTR1BDRD2HTR2AHTR1A | |
| SCHEMBL6811960 | 0.80 | HTR1D (0.78) | HTR1DHTR1BDRD2HTR2AHTR1A | |
| SCHEMBL6811572 | 0.78 | HTR1D (0.72) | HTR1DHTR1BDRD2HTR1ASLC6A4 | |
| SCHEMBL5097902 | 0.78 | HTR1D (0.72) | HTR1DHTR1BDRD2HTR2AHTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7335660-B2 | Isochroman compounds for treatment of CNS disorders | ELI LILLY AND COMPANY (US) | 2008-02-26 | — | — | US | disclosed |
| EP-1458703-B1 | ISOCHROMAN COMPOUNDS FOR TREATMENT OF CNS DISORDERS | LILLY CO ELI (US) | 2007-02-28 | — | — | EP | disclosed |
| US-20050014750-A1 | Isochroman compounds for treatment of cns disorders | ELI LILLY AND COMPANY | 2005-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014750-A1 | Isochroman compounds for treatment of cns disorders | INA, CNR2, CNR1 | HTR1D 201/4885HTR1B 185/4885DRD2 207/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.